Merck Helps/Merck Access Program

Patient Support Services Guide 2018


Merck Helps
800-727-5400
Merck Access Program
855-257-3932

Merck Helps offers a full suite of support services that facilitate access to Merck’s drugs for eligible patients who are unable to afford their Merck medications, regardless of their insurance status.

Merck’s support services include Merck Access Program (MAP) and Merck Patient Assistance Program (MPAP).

Merck Access Program
MAP provides eligible patients with access and support services, including insurance coverage for patients; benefits investigations, prior authorizations, and appeals; reimbursement; copay assistance for eligible patients; as well as referrals to MPAP.

Merck Patient Assistance Program
Eligible uninsured patients or those whose insurance does not cover their prescribed Merck medication may qualify to receive medication free of charge through MPAP.

Merck Co-pay Assistance Program
This program is available for patients with private health insurance who need assistance paying their copays for Keytruda (pembrolizumab).

Merck’s oncology and supportive care drugs are listed in the Table. For more information visit MerckHelps.com.

Eligibility

Merck Patient Assistance Program

Patients may qualify for MPAP, if:

  • They are legal residents of the United States or its territories
  • They have a prescription for a Merck medication from a licensed US healthcare provider
  • They are uninsured and/or do not have other forms of coverage for their prescription medicines
  • They are unable to afford their medication. Specifically, for Emend capsules (aprepitant), Intron A (interferon alfa-2b, recombinant), Sylatron (peginterferon alfa-2b), or Temodar (temozolomide), the patient’s household income must be ≤$48,240 for individuals, ≤$64,960 for couples, or ≤$98,400 for a family of 4. For Emend for injection (fosaprepitant dimeglumine), Keytruda, or Noxafil (posaconazole), the patient’s household income must be ≤$60,300 for 1 person, ≤$81,200 for couples, or ≤$123,000 for a family of 4.

Contact the individual programs directly for specific financial eligibility requirements.

Merck Access Program

MAP’s services are drug-­specific for Emend for injection and for Key­truda. Visit MerckAccessProgram.com or call 855-257-3932 for more information.

Merck Co-pay Assistance Program

The Merck Co-pay Assistance Program is available for patients:

  • Who are aged >18 years
  • Who have been prescribed a qualified Merck medication (Keytruda) for an FDA-approved indication
  • With private health insurance that provides coverage for the prescribed medication
  • Who meet certain financial requirements.

This program is not valid for patients covered under a government-­funded program or uninsured patients. Patients must pay the first $25 of copay per administration of their drug, up to a maximum of $25,000 per patient per calendar year.

Application & Enrollment

To enroll in MAP and/or MPAP programs, including Merck Co-pay Assistance Program, patients with their healthcare provider must complete the relevant sections of the enrollment form (available at MerckAccessProgram.com), and fax it to 855-755-0518 or mail it to the address provided on the form.

The prescribed Merck medication (Emend for injection or Keytruda), and the program the patient is applying for, must be indicated on the form. The patient’s insurance information and clinical information (including a diagnostic code) must be included.

The patient’s gross household income (including before-tax wages, pension, interest/dividends, Social Security benefits, and any other sources of income) must be supplied if the patient is applying for MPAP or Merck Co-pay Assistance Program. Patients who qualify for the program are eligible to receive their medications at no cost for up to 1 year.

Table Merck Oncology/Supportive Care Drugs

Drugs
Indications
Patient support programs

Drug
Emend capsules (aprepitant)
Indication
Nausea and vomiting caused by chemotherapy
Patient support program

Drug
Emend for injection (fosaprepitant dimeglumine)
Indication
Nausea and vomiting caused by chemotherapy

Drug
Intron A (interferon alfa-2b, recombinant) for injection
Indication
Hairy-cell leukemia; malignant melanoma; follicular lymphoma; AIDS-related Kaposi’s sarcoma
Patient support program

Drug
Keytruda (pembrolizumab)

Indication
Unresectable or metastatic melanoma; metastatic NSCLC with high PD-L1 expression; metastatic NSCLC with PD-L1 and disease progression during or after platinum-containing chemotherapy; metastatic nonsquamous NSCLC, in combination with pemetrexed and carboplatin; recurrent/metastatic head and neck squamous-cell cancer that progressed during or after platinum-containing chemotherapy; refractory/relapsed classical Hodgkin lymphoma; locally advanced/metastatic urothelial carcinoma in patients ineligible for cisplatin-containing chemotherapy; locally advanced or metastatic urothelial carcinoma that progressed during or after platinum-containing chemotherapy; unresectable or metastatic MSI-H or MMR-D solid tumors progressing after treatment; recurrent locally advanced/metastatic gastric or gastroesophageal junction adenocarcinoma with PD-L1 and disease progression during or after ≥2 therapies, including fluoropyrimidine- and platinum-containing chemotherapy, and if appropriate, HER2-targeted therapy

Drug
Noxafil (posaconazole)
Indication
Invasive Aspergillus and Candida infections associated with hematologic cancer or stem-cell transplantation

Drug
Sylatron (peginterferon alfa-2b)
Indication
Melanoma
Patient support program

Drug
Temodar (temozolomide)
Indication
Newly diagnosed glioblastoma multiforme, concomitantly with radiotherapy, then as maintenance treatment in adults; refractory anaplastic astrocytoma and disease progression with a nitrosourea- and procarbazine-based regimen
Patient support program

MMR-D indicates mismatch repair–deficient; MSI-H, microsatellite instability-high; NSCLC, non–small-cell lung cancer.